The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Constantine S. Tam, Andrew W. Roberts, Carmen DiCorleto et al.|Blood|2015

Cited by 111